Clinical Scorecard: The Prognostic Role of Tumor Siglec-15 Expression in Solid Tumors: A Comprehensive Meta-Analysis and Systematic Review

At a Glance

Key Highlights

• High Siglec-15 expression is associated with poorer overall survival (OS) and disease-free/recurrence-free survival (DFS/RFS).
• No significant association found for progression-free survival.
• Siglec-15 expression inversely correlates with PD-L1 positivity.
• Tumor-specific analyses show worse OS in colorectal cancer, gastric cancer, and osteosarcoma.
• Further prospective studies are needed to validate findings and develop standardized assessment strategies.

Guideline-Based Recommendations

Diagnosis

• Evaluate tumoral Siglec-15 expression in patients with solid tumors.

Management

• Consider Siglec-15 as a potential therapeutic target in immunotherapy.

Monitoring & Follow-up

• Monitor overall survival and disease-free survival in relation to Siglec-15 expression levels.

Risks

• High Siglec-15 expression may indicate poorer prognosis in certain cancer types.

Patient & Prescribing Data

Patients with solid tumors, particularly those with high Siglec-15 expression.

Anti-Siglec-15 antibodies are under clinical evaluation, showing potential for patients unlikely to respond to PD-1/PD-L1 blockade.

Clinical Best Practices

• Utilize standardized assessment strategies for Siglec-15 expression.
• Incorporate Siglec-15 evaluation in treatment planning for solid tumors.

Related Resources & Content